Potential and emerging therapeutics for HHT

2.

Zhang

E

,

Virk

ZM

,

Rodriguez-Lopez

J

,

Al-Samkari

H

.

Hereditary hemorrhagic telangiectasia may be the most morbid inherited bleeding disorder in women

.

2024

;

8

(

12

):

3166

-

3172

.

3.

Ruiz

S

,

Zhao

H

,

Chandakkar

P

, et al.

Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models

.

J Clin Investig

.

2020

;

130

(

2

):

942

-

957

.

4.

Brinjikji

W

,

Iyer

VN

,

Sorenson

T

,

Lanzino

G

.

Cerebrovascular manifestations of hereditary hemorrhagic telangiectasia

.

Stroke

.

2015

;

46

(

11

):

3329

-

3337

.

5.

Bernabeu

C

,

Bayrak-Toydemir

P

,

McDonald

J

,

Letarte

M

.

Potential Second- Hits in Hereditary Hemorrhagic Telangiectasia

.

J Clin Med

.

2020

;

9

(

11

).

6.

Torsney

E

,

Charlton

R

,

Diamond

AG

,

Burn

J

,

Soames

JV

,

Arthur

HM

.

Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality

.

Circulation

.

2003

;

107

(

12

):

1653

-

1657

.

7.

McDonald

J

,

Wooderchak-Donahue

W

,

VanSant Webb

C

,

Whitehead

K

,

Stevenson

DA

,

Bayrak-Toydemir

P

.

Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era

.

Front Genet

.

11

February

2015

;

6

:

1

.

8.

Wooderchak-Donahue

WL

,

McDonald

J

,

O'Fallon

B

, et al.

BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia

.

Am J Hum Genet

.

2013

;

93

(

3

):

530

-

537

.

9.

Hammill

AM

,

Wusik

K

,

Kasthuri

RS

.

Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management

.

Hematology

.

2021

;

2021

(

1

):

469

-

477

.

10.

Kasthuri

RS

,

Montifar

M

,

Nelson

J

, et al.

Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia [published online 22 June 2017]

.

Am J Hematol

.

11.

Murray

E

,

Taylor

J

,

Hountras

P

.

A case of high-output heart failure

.

CHEST

.

2022

;

161

(

1

):

e23

-

e28

.

12.

McDonald

NM

,

Ramos

GP

,

Sweetser

S

.

SMAD4 mutation and the combined juvenile polyposis and hereditary hemorrhage telangiectasia syndrome: a single center experience

.

Int J Colorectal Dis

.

2020

;

35

(

10

):

1963

-

1965

.

13.

McAllister

KA

,

Grogg

KM

,

Johnson

DW

, et al.

Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1

.

Nat Genet

.

1994

;

8

(

4

):

345

-

351

.

14.

Mitchell

A

,

Adams

LA

,

MacQuillan

G

,

Tibballs

J

,

vanden Driesen

R

,

Delriviere

L

.

Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia

.

Liver Transpl

.

2008

;

14

(

2

):

210

-

213

.

15.

Ardelean

DS

,

Jerkic

M

,

Yin

M

, et al.

Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment

.

Angiogenesis

.

2014

;

17

(

1

):

129

-

146

.

16.

Shao

ES

,

Lin

L

,

Yao

Y

,

Boström

KI

.

Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells

.

Blood

.

2009

;

114

(

10

):

2197

-

2206

.

17.

Tual-Chalot

S

,

Oh

SP

,

Arthur

HM

.

Mouse models of hereditary hemorrhagic telangiectasia: recent advances and future challenges

.

Front Genet

.

11

February

2015

;

6

:

25

.

18.

Lebrin

F

,

Srun

S

,

Raymond

K

, et al.

Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia

.

Nat Med

.

2010

;

16

(

4

):

420

-

428

.

19.

Dupuis-Girod

S

,

Rivière

S

,

Lavigne

C

, et al.

Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: a national, randomized multicenter trial

.

J Intern Med

.

2023

;

294

(

6

):

761

-

774

.

20.

Al-Samkari

H

,

Kasthuri

RS

,

Parambil

JG

, et al.

An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study

.

Haematologica

.

2021

;

106

(

8

):

2161

-

2169

.

21.

Dupuis-Girod

S

,

Ginon

I

,

Saurin

JC

, et al.

Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output

.

JAMA

.

2012

;

307

(

9

):

948

-

955

.

22.

Harrison

L

,

Kundra

A

,

Jervis

P

.

The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review

.

J Laryngol Otol

.

2018

;

132

(

10

):

866

-

871

.

23.

Al-Samkari

H

, et al.

Pomalidomide for epistaxis in hereditary hemorrhagic telangiectasia

.

NEJM

.

2024

;

391

(

11

):

1015

-

1027

.

24.

Parambil

JG

,

Gossage

JR

,

McCrae

KR

, et al.

Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia

.

Angiogenesis

.

2022

;

25

(

1

):

87

-

97

.

25.

Karar

J

,

Maity

A

.

PI3K/AKT/mTOR pathway in angiogenesis

.

Front Mol Neurosci

.

1

December

2011

;

4

:

51

.

26.

Álvarez-Hernández

P

,

Patier

JL

,

Marcos

S

, et al.

Tacrolimus as a promising drug for epistaxis and gastrointestinal bleeding in HHT

.

J Clin Med

.

2023

;

12

(

23

):

7410

.

27.

Vázquez

C

,

Gonzalez

ML

,

Ferraris

A

,

Bandi

JC

,

Serra

MM

.

Bevacizumab for treating hereditary hemorrhagic telangiectasia patients with severe hepatic involvement or refractory anemia

.

PLoS One

.

2020

;

15

(

2

):

e0228486

.

28.

Al-Samkari

H

,

Kritharis

A

,

Rodriguez-Lopez

JM

,

Kuter

DJ

.

Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia

.

J Intern Med

.

2019

;

285

(

2

):

223

-

231

.

29.

Guilhem

A

,

Fargeton

AE

,

Simon

AC

, et al.

Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients

.

PLoS One

.

2017

;

12

(

11

):

e0188943

.

30.

Iyer

VN

,

Apala

DR

,

Pannu

BS

, et al.

Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia–related epistaxis and gastrointestinal bleeding

.

Mayo Clin Proc

.

2018

;

93

(

2

):

155

-

166

.

31.

Faughnan

ME

,

Gossage

JR

,

Chakinala

MM

, et al.

Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia

.

Angiogenesis

.

2019

;

22

(

1

):

145

-

155

.

32.

Invernizzi

R

,

Quaglia

F

,

Klersy

C

, et al.

Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study

.

Lancet Haematol

.

2015

;

2

(

11

):

e465

-

e473

.